FIG 4.

Neutralization of a SHIV1157ipd3N4 Env pseudotype by vaccinated monkey serum. Dot plots were generated to show the residual percent infectivity of the SHIV1157ipd3N4 Env G13.10 by 1:50-diluted, heat-inactivated monkey serum collected at week 40/41 (A) and week 58 (B) arranged by vaccination group. The vaccination modalities for each arm are indicated below the graph. A horizontal bar indicates the median percent infectivity for each group. A Kruskal-Wallis test was performed to determine whether the levels of neutralization in each vaccination group were significantly different from those for the animals that received DDMMM, and significant differences are indicated by asterisks (***, P < 0.001; ****, P < 0.0001). The results for the protein-only groups that received 3M-052 adjuvant in trials M19 and M21 were significantly different from those for the DDMMM group. The adjuvant used with the protein immunizations is indicated as Adjuplex (ADJ) or 3M-052.